A high risk for in-hospital mortality, ICU admittance and mechanical ventilation was found in patients with COVID-19 plus a community-acquired bacterial infection, according to study results published in Critical Care.“Although confirmed bacteremic coinfections are rare in COVID-19, less than 4 percent of inpatient admissions, our results show that COVID-19 patients with these coinfections
Live biotherapeutic product reduces lung damage in neonatal mouse model of chronic lung disease miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
UAB spinoff receives $3 million in seed funding to develop probiotic formulations for lung health
A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding.
ResBiotic Inc. spun off from UAB last year will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the UAB Department of Pediatrics, Division of Neonatology. The seed round was funded from a private equity syndicate led by Birmingham-based investment firm Timberline Holdings.
ResBiotic s first product aims to supplement the nutritional needs in chronic lung diseases. The product was developed in Lal s Pulmonary Microbiome Lab at UAB, with research and expertise from UAB s Microbiome Center, Lung Health Center, and the Translational Research in Normal & Disordered Development program.